LEXICON PHARMACEUTICALS INC (LXRX) Stock News
NASDAQ:LXRX - Nasdaq - US5288723027 - Common Stock - Currency: USD
LXRX Latest News, Press Relases and Analysis
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)
Oral presentation on study demonstrating the ability of sotagliflozin to reduce the risk of hypoglycemic events regardless of kidney function in people...
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)
Oral presentation on study demonstrating the ability of sotagliflozin to reduce the risk of hypoglycemic events regardless of kidney function in people with type 1 diabetes
ETFs to Capitalize on the Novo Nordisk-Septerna Deal
Novo Nordisk announces a $2.2 billion deal with Septerna to tap the growing obesity treatment market.
KURA Stock Rises More Than 15% This Past Week: Here's Why
Kura Oncology shares rise this week after the FDA accepts its NDA for ziftomenib, a potential first-in-class treatment for NPM1-mutant AML.
TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy
Tempest jumps after EMA grants orphan drug status to its liver cancer candidate, amezalpat, based on positive study data.
Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio?
ZTS jumps 13% in a month as strong new product sales, strategic deals, and rising earnings estimates boost investor confidence.
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success
LYRA skyrockets 356% after its lead nasal implant, LYR-210, meets key goals in a pivotal phase III chronic rhinosinusitis study.
JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer
Johnson & Johnson's niraparib combo significantly delays prostate cancer progression in HRR-altered patients with strong phase III data.
MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study
Merck reports promising response rates for its ADC zilovertamab vedotin in relapsed DLBCL and KRAS inhibitor MK-1084 in solid tumors.
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study
Intellia stock tanks after a patient in its phase III study evaluating gene therapy candidate nex-z in ATTR-CM experiences serious liver enzyme elevation.
IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus
Immunovant stock rises on encouraging fourth-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.
BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications
Bristol Myers' Opdivo SC wins EU approval as the first PD-1 inhibitor for subcutaneous use across multiple solid tumor indications.
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer
Candel stock rises as FDA grants RMAT tag to CAN-2409 after phase III success in prostate cancer. BLA submission is planned at the end of 2026.
RCKT Stock Tanks on Patient Death in Danon Disease Study
Rocket Pharmaceuticals plunges after a patient death in its Danon disease study, prompting a voluntary dosing pause. The FDA puts a clinical hold on the study.
TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate
TEVA starts IND-enabling studies for BD9, a dual-targeting multibody for asthma and eczema. Shares rise on the news.
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval
Verastem Oncology jumps 22% on FDA nod for Avmapki Fakzynja, the first approved KRAS-mutant LGSOC therapy, with strong early data in a pancreatic cancer study.
AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer
AstraZeneca wins CHMP nod for Imfinzi combo in muscle-invasive bladder cancer, based on data from the phase III NIAGARA study.
GSK Gets CHMP Nod for Blenrep Combos in Multiple Myeloma
GSK wins CHMP nod for Blenrep combos in relapsed or refractory multiple myeloma. A decision in the EU is expected in the third quarter of 2025.
SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease
SWTX wins CHMP backing for mirdametinib in NF1-PN. EU nod is expected in the third quarter of 2025.
Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential
We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) was one of the stocks that was covered in that article. Wall Street analysts believe LXRX has a 285% upside potential over the next 12 months. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is a biopharmaceutical company with a pioneering approach […]
SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology
Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates
Company had a strong start to 2025, emerging as an R&D-focused organization Exclusive license agreement with Novo Nordisk for LX9851 executed;...
Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates
Agenus (AGEN) delivered earnings and revenue surprises of 36.02% and 14.73%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: AGEN
Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates
Femasys (FEMY) delivered earnings and revenue surprises of -35.29% and 77.27%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: FEMY
Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference
THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will...
Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first...
Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will...